Peptides DB
Research-centric peptide and protocol reference hub
Study 59 of 65HCG (Human Chorionic Gonadotropin) literatureThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · Observational2026

Efficacy of hysteroscopic curettage and niche resection in type II and III cesarean scar pregnancies.

Hysteroscopic curettage combined with diverticulum canal-opening may improve surgical outcomes in cesarean scar pregnancies, but long-term safety remains uncertain.

Read at The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal ObstetriciansAdd to compare

Where it sits

this study against the rest of the hcg (human chorionic gonadotropin) corpus
9
Preclinical
51
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study evaluated the efficacy and safety of hysteroscopic curettage combined with cesarean scar diverticulum canal-opening after focused ultrasound ablation surgery in patients with type II and III cesarean scar pregnancies. A total of 105 patients were analyzed, with the observation group undergoing combined treatment and the control group receiving hysteroscopic curettage alone. The observation group demonstrated improved surgical parameters and outcomes compared to the control group.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
20 (15,25) min vs 25 (20,31) min operation time, p=0.001n=1052026

Abstract

The authors’ words, as The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians supplied them

<h4>Introduction</h4>To evaluate the efficacy and safety of hysteroscopic curettage combined with cesarean scar diverticulum canal-opening after focused ultrasound ablation surgery (FUAS) pretreatment in patients with type II and III cesarean scar pregnancy (CSP).<h4>Methods</h4>Clinical data of 105 patients with type II/III CSP treated between January 2019 and October 2022 were retrospectively analyzed. All patients received FUAS pretreatment. The observation group (<i>n</i> = 47) underwent hysteroscopic curettage combined with niche canal-opening, while the control group (<i>n</i> = 58) received hysteroscopic curettage alone. Surgical parameters, postoperative recovery, complications, reintervention rates, and menstrual outcomes were compared.<h4>Results</h4>The observation group had significantly shorter operation time [20 (15,25) vs. 25 (20,31) min, <i>p</i> = 0.001], less intraoperative blood loss [5 (5,10) vs. 10 (10,50) mL, <i>p</i> = 0.002], lower complication rate [4.3% vs. 17.2%, <i>p</i> = 0.038], and lower reintervention rate [4.3% vs. 19.0%, <i>p</i> = 0.023]. No between-group differences were observed in postoperative hemoglobin decline, hospital stay, vaginal bleeding duration, human chorionic gonadotropin normalization time, menstrual recovery time, or residual scar myometrial thickness (all <i>p</i> > 0.05). Among patients with preoperative prolonged menstruation, menstrual duration improved in both groups (<i>p</i> < 0.05), with a higher improvement rate in the observation group [75.0% vs. 23.1%, <i>p</i> = 0.005].<h4>Conclusions</h4>FUAS pretreatment combined with hysteroscopic surgery is safe and effective for type II/III CSP. Adding diverticulum canal-opening to hysteroscopic curettage further optimized surgical outcomes by reducing operation time, intraoperative blood loss, complication rates, and the need for reintervention, while also significantly improving prolonged menstruation. This combined strategy may serve as an optimized minimally invasive alternative for patients desiring fertility, though long-term reproductive safety requires further verification.

Background

This paper addresses the clinical challenge of managing type II and III cesarean scar pregnancies, which can complicate future pregnancies and pose risks to maternal health. Previous studies have indicated various surgical approaches, but there is limited evidence on the combined efficacy of focused ultrasound ablation and hysteroscopic techniques. This study aims to provide insights into optimizing surgical outcomes for these patients.

Methods

This retrospective analysis included 105 patients with type II/III cesarean scar pregnancies treated from January 2019 to October 2022. Patients received focused ultrasound ablation pretreatment, with the observation group (n=47) undergoing hysteroscopic curettage combined with niche canal-opening, while the control group (n=58) received hysteroscopic curettage alone. Surgical parameters, postoperative recovery, complications, reintervention rates, and menstrual outcomes were the primary outcome measures.

Results

The observation group had a significantly shorter operation time of 20 (15,25) minutes compared to 25 (20,31) minutes in the control group (p=0.001). Intraoperative blood loss was also significantly less in the observation group at 5 (5,10) mL versus 10 (10,50) mL (p=0.002). The complication rate was lower in the observation group at 4.3% compared to 17.2% in the control group (p=0.038), and the reintervention rate was 4.3% versus 19.0% (p=0.023). No significant differences were found in postoperative hemoglobin decline, hospital stay, vaginal bleeding duration, human chorionic gonadotropin normalization time, menstrual recovery time, or residual scar myometrial thickness (all p>0.05).

Interpretation

The findings suggest that the addition of diverticulum canal-opening to hysteroscopic curettage may enhance surgical outcomes for cesarean scar pregnancies. While the results are statistically significant, the clinical significance of some findings, such as the reduction in operation time and blood loss, may vary based on individual patient contexts. The retrospective nature of the study and lack of long-term follow-up limit the ability to draw definitive conclusions about long-term reproductive safety and effectiveness.

Key findings

  • 20 (15,25) min vs 25 (20,31) min operation time, p=0.001
  • 5 (5,10) mL vs 10 (10,50) mL intraoperative blood loss, p=0.002
  • 4.3% vs 17.2% complication rate, p=0.038
  • 4.3% vs 19.0% reintervention rate, p=0.023
  • 75.0% vs 23.1% improvement rate in menstrual duration for prolonged menstruation, p=0.005

Limitations

  • retrospective study design
  • small sample size (n=105)
  • lack of long-term follow-up
  • potential biases in data collection
  • no human chorionic gonadotropin normalization time reported

Elsewhere in the HCG (Human Chorionic Gonadotropin) corpus

BEarly pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma.Seminars in oncology · 2026 · n=1 · Not reported in abstract.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2024 · n=177 · Treatment success occurred in 94 of 177 women (53.1%).HumanBSuccessful fertility-preserving management of a viable cesarean scar ectopic pregnancy: a case report.Case reports in women's health · 2026 · n=1 · Estimated blood loss of 20 mL.HumanBEndometrial ultrasound features associated with methotrexate success in tubal ectopic pregnancy: a prospective case series.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · 53.1% treatment success in 177 women.HumanCSR-18292 Alters Oocyte Competence and Ovarian Transcriptomic Dynamics in Female Micebiorxiv-preprint · 2026 · Not reported in abstract.AnimalBHigh-grade endometrioid carcinoma arising from uterine serosal endometriosis with focal choriocarcinomatous differentiation and embryonal carcinoma-like morphology: a case report and literature reviewbiorxiv-preprint · 2023 · n=1 · Serum β-hCG remained persistently below 1 mIU/mL throughout follow-up.Human